Abstract 116P
Background
RAS mutation has become an important part of assessment of patients with colorectal cancer (CRC), but its role in colorectal cancer patients with initially unresectable liver metastases has yet to be elaborated. We aim to assess the role of RAS mutation on convertion of patients with initially unresectable colorectal liver metastases (CLMs).
Methods
We identified CRC patients who initially with unresectable liver metastases during January 2012 to December 2017 in Zhongshan Hospital Fudan University. The association between RAS status of primary tumor and characteristics of patients were analyzed. Conversion rates was determined.
Results
A total of consecutive 433 CLM patients with available RAS status were evaluated in this study, KRAS mutation rates was 41.5%, BRAF was 6.7% and NRAS was 1.6%. 258 patients were RAS wild type and 185 patients were mutant. RAS mutation were associated with right colon cancer (P = 0.006) and lymph node metastasis (P = 0.017). Among RAS wild type patients, 56.2% (145/258) received Cetuximab plus chemotherapy treatment, 7.8% (20/258) received Bevacizumab plus chemotherapy and the others received chemotherapy only. Among RAS mutant patients, 50.8% (94/185) received Bevacizumab plus chemotherapy and 49.2% (91/185) received chemotherapy only. RAS wild type patients had a better objective response rate (52.3% vs 37.3%, p = 0.011) and higher conversion rate (24.0% vs 12.4%, P = 0.002) compare with RAS mutant patients. For RAS wild type group, patients with Cetuximab plus chemotherapy, Bevacizumab plus chemotherapy and chemotherapy only have a conversion resection rate of 31.5% ,20% and 14.3% respectively P = 0.05 for RAS mutation group, Bevacizumab plus chemotherapy had a similar conversion resection rate compared with chemotherapy only (12.6% VS 11.3%, P = 0.815).
Conclusions
RAS wild type indicated a better conversion rate for patients with initially unresectable colorectal liver metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract